Vbi Vaccines Inc

Safety Score

Market Cap $12.29K
Debt $97.49M
Cash $12.60M
EV $84.91M
FCF -$51.48M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$83.99M
EBIT	-$72.15M
ROA	-96%
FCF	-$51.48M
Equity	-$5.47M
Growth Stability	1
PE	-0
PB	-0
P/FCF	-0
P/S	0
Price/Cash	1.02K
Debt/Equity	-17.83
Debt/FCF	-1.89
Net Margins	-1K%
Op. Margins	-767%
Sales Growth YoY	150%
Sales Growth QoQ	42%
Sales CAGR	8%
Equity CAGR	-6%
Earnings Growth YoY	-35%

Earnings Growth QoQ	11K%
Sales CAGR 5Y	11%
Equity CAGR 5Y	-35%
Earnings CAGR 3Y	188%
Sales CAGR 3Y	188%
Equity CAGR 3Y	-72%
Market Cap	$12.29K
Revenue	$9.41M
Assets	$75.44M
Total Debt	$97.49M
Cash	$12.60M
Shares Outstanding	24.58M
EV	84.91M
Safety Score	43%
Working Capital	-51.23M
Current Ratio	0.34
Shares Growth 3y	7%
Equity Growth QoQ	-173%
Equity Growth YoY	-112%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

VBI Vaccines Inc. VBI is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles VLPs including a proprietary enveloped VLP eVLP platform technology VBI develops vaccine candidates that mimic the natural presentation of viruses designed to elicit the innate power of the human immune system.

SEC Filings

Direct access to Vbi Vaccines Inc (VBIVQ) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vbi Vaccines Inc compare to its competitors?

Not enough data to generate a comparison chart between Vbi Vaccines Inc and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Vbi Vaccines Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vbi Vaccines Inc Discounted Cash Flow

Fully customizable DCF calculator online for Vbi Vaccines Inc.

Years

Calculation mode

= -$515M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$51M	-$51M	-$51M	-$51M	-$51M	-$51M	-$51M	-$51M	-$51M	-$51M	-$51M	-$515M
DCF		-$47M	-$43M	-$39M	-$35M	-$32M	-$29M	-$26M	-$24M	-$22M	-$20M	-$198M
Value	-$515M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	05/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-3K%	-	-5K%	-2K%	-2K%	-4K%	-11K%	-10K%	-1K%	-1K%
ROA	-	-	-	-44%	-43%	-21%	-32%	-53%	-92%	-96%
ROE	-	-	-33%	-65%	-62%	-27%	-48%	-177%	-1K%	-

Bad Net Margins (-1.47K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	05/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-0.29	-0.57	-0.34	-0.77	-0.63	-1.64	-1.89
Debt over Equity	-	-	0.12	0.15	0.34	0.1	0.22	0.76	13.49	-17.83
Growth Stability	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-1.89)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-17.83)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	05/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	288%	-34%	-52%	-41%	71%	702%	11%
Earnings YoY growth	-	-140%	-471%	63%	-14%	-16%	51%	62%	-17%	-
Equity YoY growth	-	-	-	-18%	-10%	95%	-16%	-55%	-88%	-35%
FCF YoY growth	-	-	-	61%	2%	-8%	-13%	86%	-21%	-